Comprehensive M&A data with integrated detailed company information

Recursion to grow its pipeline with Vium
Posted on Wednesday, 29 July 2020 06:55
Recursion Pharmaceuticals has bought US-based digital vivarium company Vium.

The transaction will allow the buyer to grow its drug discovery pipeline, as well as its programmes developed jointly with large pharmaceutical partners.

Financial terms were not disclosed.

California-headquartered Vium is a translational medical company which focuses on improving drug development through the creation of more precise and reproducible diseases models.

The group works across a range of therapeutic areas, including immunology, phenotyping and inflammation and fibrosis.

Its digital platform provides physiological biomarkers to help companies determine which compounds should be advanced to the clinic.

Vium’s technology captures physiological metrics and behaviours non-invasively and collects information that can lead to more replicable studies.

By providing researchers with this data, the platform allows them to identify which biomarkers are the strongest indicators of disease.

Through its Vium Smart Housing system, the target also offers 49 individually ventilated cages, internal back-up storage for up to 48 hours and enables customers to access and view studies from their browser.

Launched in 2013, Vium’s clients include pharmaceutical and biotechnology companies, academic researchers and novel therapeutic discovery and development laboratories.

Chris Gibson, chief executive of the buyer, said the addition of the target will complement and augment its existing in vitro datasets, while advancing its strategy of decoding biology to help improve patient’s lives.

Vium’s chief executive, Laura Schaevitz, noted: “We are excited to focus exclusively on building a large in vivo data set for Recursion’s digital biology platform, potentially enabling an even broader pipeline of medicines.”

Located in Salt Lake City, the acquiror provides automation, artificial intelligence and machine learning-based services, among others, to help discover novel therapeutics.

Its pipeline includes Rec-994, a drug used to treat cerebral cavernous malformation, a rare genetic disease that affects up to 1.50 million people in the US, according to its website.

© Zephus Ltd